BARICITINIB (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
oral; 2mg once daily
Baricitinib increases the risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants (e.g., methotrexate, corticosteroids), Closely monitor for developing signs and symptoms of infection during and after treatment, including the possible development of TB in patients who tested negative for latent TB before initiating baricitinib. Avoid use of live vaccines with BARICITINIB. Paediatric: Safety and efficacy in pediatric patients have not been established Pregnancy: Data not sufficient Lactation: Breast feeding is not recommended Elderly: No overall differences in safety or effectiveness have been observed between elderly and other adult patients.
Upper respiratory tract infections, Nausea, Increased liver function tests, Platelet elevations, Acne, Herpes simplex infection, Low white blood cell count (neutropenia),thrombosis, Lymphoma and other malignancies
strong OAT3 inhibitors (such as probenecid)